We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

89 hedge funds and large institutions have $310M invested in Merrimack Pharmaceuticals, Inc. in 2013 Q2 according to their latest regulatory filings, with 89 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more call options, than puts

Call options by funds: $413K | Put options by funds: $302K

Holders
89
Holders Change
+89
Holders Change %
–
% of All Funds
2.9%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
89
Increased
–
Reduced
–
Closed
–
Calls
$413K
Puts
$302K
Net Calls
+$111K
Net Calls Change
+$111K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$107M +$88.8M +2,025,371 New
CS
2
Credit Suisse
Switzerland
$31.1M +$25.7M +585,576 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$25.3M +$20.9M +477,837 New
Jennison Associates
4
Jennison Associates
New York
$21.1M +$17.5M +399,144 New
BFA
5
BlackRock Fund Advisors
California
$19.9M +$16.4M +374,458 New
Westfield Capital Management
6
Westfield Capital Management
Massachusetts
$10.1M +$8.31M +189,614 New
BIT
7
BlackRock Institutional Trust
California
$9.14M +$7.56M +172,399 New
Bank of America
8
Bank of America
North Carolina
$9.14M +$7.55M +172,334 New
State Street
9
State Street
Massachusetts
$7.86M +$6.5M +148,333 New
FCM
10
Farallon Capital Management
California
$7.18M +$5.95M +135,684 New
Bank of New York Mellon
11
Bank of New York Mellon
New York
$7.02M +$5.8M +132,314 New
FAM
12
Fred Alger Management
New York
$5.28M +$4.36M +99,483 New
MF
13
Magnetar Financial
Illinois
$5.08M +$4.21M +95,940 New
O
14
OppenheimerFunds
New York
$5.02M +$4.16M +94,821 New
TCM
15
Tekla Capital Management
Massachusetts
$3.62M +$3M +68,329 New
Northern Trust
16
Northern Trust
Illinois
$3.36M +$2.78M +63,412 New
TCIM
17
TIAA CREF Investment Management
New York
$2.48M +$2.05M +46,867 New
JP Morgan Chase
18
JP Morgan Chase
New York
$2.36M +$1.95M +44,578 New
PI
19
Putnam Investments
Massachusetts
$2.02M +$1.67M +38,130 New
CT
20
Cambridge Trust
Massachusetts
$1.61M +$1.33M +30,377 New
BIM
21
BlackRock Investment Management
Delaware
$1.59M +$1.32M +30,025 New
Charles Schwab
22
Charles Schwab
California
$1.14M +$915K +20,884 New
Alyeska Investment Group
23
Alyeska Investment Group
Illinois
$1.09M +$903K +20,601 New
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$1.07M +$882K +20,125 New
FIG
25
Fortress Investment Group
New York
$1.06M +$880K +20,082 New
1
2 3 4

MACK Hedge Fund Activity: Q2 2013 in Review

89 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2013, worth a combined $310M.

Buyers outnumbered sellers: 89 funds opened new MACK positions and 0 closed out — a net gain of 89 holders — while 0 added to existing stakes and 0 trimmed.

  • 89 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $310M of Merrimack Pharmaceuticals, Inc. stock for Q2 2013.
  • 89 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2013 and 0 closed out, a net change of +89 holders.

Based on aggregated 13F filings for Q2 2013.